Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRIX |
---|---|---|
09:32 ET | 6402 | 18.99 |
09:34 ET | 2053 | 18.99 |
09:36 ET | 1114 | 18.95 |
09:38 ET | 1664 | 19.035 |
09:39 ET | 464 | 18.93 |
09:41 ET | 1536 | 19.015 |
09:43 ET | 264 | 19.0337 |
09:45 ET | 1274 | 18.965 |
09:48 ET | 932 | 18.945 |
09:50 ET | 4063 | 19.01 |
09:52 ET | 1464 | 18.95 |
09:54 ET | 2894 | 18.98 |
09:56 ET | 3642 | 18.855 |
09:57 ET | 764 | 18.855 |
09:59 ET | 6565 | 18.985 |
10:01 ET | 3197 | 19.28 |
10:03 ET | 664 | 19.33 |
10:06 ET | 17903 | 19.23 |
10:08 ET | 1791 | 19.285 |
10:10 ET | 2150 | 19.33 |
10:12 ET | 11187 | 19.285 |
10:14 ET | 9240 | 19.495 |
10:15 ET | 8143 | 19.54 |
10:17 ET | 3622 | 19.59 |
10:19 ET | 300 | 19.65 |
10:21 ET | 2224 | 19.78 |
10:24 ET | 10948 | 19.94 |
10:26 ET | 400 | 19.935 |
10:28 ET | 2300 | 19.87 |
10:30 ET | 509 | 19.845 |
10:32 ET | 702 | 19.9 |
10:33 ET | 6209 | 19.75 |
10:35 ET | 1050 | 19.87 |
10:37 ET | 800 | 19.81 |
10:39 ET | 300 | 19.78 |
10:42 ET | 900 | 19.735 |
10:44 ET | 1047 | 19.641 |
10:46 ET | 200 | 19.625 |
10:48 ET | 920 | 19.63 |
10:50 ET | 1000 | 19.67 |
10:51 ET | 1503 | 19.66 |
10:53 ET | 900 | 19.635 |
10:55 ET | 430 | 19.6275 |
10:57 ET | 2627 | 19.69 |
11:00 ET | 2433 | 19.71 |
11:02 ET | 1833 | 19.67 |
11:04 ET | 100 | 19.71 |
11:06 ET | 300 | 19.7 |
11:08 ET | 1315 | 19.695 |
11:09 ET | 1900 | 19.71 |
11:11 ET | 100 | 19.71 |
11:13 ET | 1300 | 19.685 |
11:15 ET | 3536 | 19.655 |
11:18 ET | 100 | 19.66 |
11:20 ET | 2360 | 19.7 |
11:22 ET | 3301 | 19.68 |
11:24 ET | 5396 | 19.7 |
11:26 ET | 300 | 19.67 |
11:27 ET | 1000 | 19.69 |
11:29 ET | 1500 | 19.6625 |
11:31 ET | 2789 | 19.61 |
11:33 ET | 1400 | 19.61 |
11:36 ET | 2570 | 19.445 |
11:38 ET | 100 | 19.49 |
11:40 ET | 100 | 19.485 |
11:42 ET | 210 | 19.48 |
11:44 ET | 327 | 19.53 |
11:45 ET | 1800 | 19.48 |
11:47 ET | 200 | 19.485 |
11:49 ET | 300 | 19.475 |
11:51 ET | 902 | 19.515 |
11:54 ET | 771 | 19.515 |
11:56 ET | 1600 | 19.54 |
11:58 ET | 300 | 19.525 |
12:00 ET | 1000 | 19.53 |
12:02 ET | 1177 | 19.5645 |
12:03 ET | 3823 | 19.59 |
12:05 ET | 200 | 19.575 |
12:07 ET | 1000 | 19.63 |
12:09 ET | 900 | 19.56 |
12:12 ET | 400 | 19.56 |
12:14 ET | 2411 | 19.55 |
12:16 ET | 100 | 19.51 |
12:18 ET | 1386 | 19.495 |
12:20 ET | 600 | 19.5 |
12:21 ET | 300 | 19.52 |
12:23 ET | 1006 | 19.475 |
12:25 ET | 1227 | 19.575 |
12:27 ET | 400 | 19.6 |
12:30 ET | 800 | 19.56 |
12:32 ET | 100 | 19.53 |
12:34 ET | 200 | 19.555 |
12:36 ET | 100 | 19.55 |
12:38 ET | 600 | 19.55 |
12:39 ET | 1780 | 19.5 |
12:41 ET | 2222 | 19.41 |
12:43 ET | 701 | 19.445 |
12:45 ET | 700 | 19.48 |
12:48 ET | 825 | 19.461 |
12:50 ET | 2514 | 19.505 |
12:52 ET | 1226 | 19.54 |
12:54 ET | 2471 | 19.56 |
12:56 ET | 5862 | 19.48 |
12:57 ET | 8555 | 19.43 |
12:59 ET | 57786 | 19.41 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nurix Therapeutics Inc | 1.2B | -7.3x | --- |
Vir Biotechnology Inc | 1.2B | -2.2x | --- |
Arcutis Biotherapeutics Inc | 1.1B | -3.3x | --- |
Prothena Corporation PLC | 1.1B | -6.2x | --- |
Immatics NV | 1.2B | -11.2x | --- |
Silence Therapeutics PLC | 839.6M | -15.3x | --- |
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.2B |
---|---|
Revenue (TTM) | $80.9M |
Shares Outstanding | 59.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.23 |
EPS | $-2.65 |
Book Value | $4.12 |
P/E Ratio | -7.3x |
Price/Sales (TTM) | 14.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -194.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.